No quarterly revenue total was found in Hepion Pharmaceuticals, Inc.'s SEC filings.
Hepion Pharmaceuticals, Inc. (HEPA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-1.25M
-19.7% vs year-ago quarter
Operating cash flow
$-1.39M
-1.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.08
+11.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
90.22M
+676.4% vs year-ago quarter
Net cash
$1.83M
Q4 FY2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HEPA (OTC), CTRVP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Red Bank, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583771
- Former names
- ContraVir Pharmaceuticals, Inc. (until Jul 23, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.2M | -$798,509 | -$609,683 | -$527,902 | -$1.7M |
| Net income | -$1.2M | -$810,791 | -$656,885 | -$472,506 | -$1.0M |
| Diluted EPS | -$0.08 | -$0.07 | -$0.06 | -$0.04 | -$0.09 |
| Operating cash flow | -$1.4M | $578,584 | -$332,775 | -$445,963 | -$1.4M |
| Total assets | $1.9M | $2.7M | $3.1M | $3.7M | $4.5M |
| Total liabilities | $648,923 | $848,747 | $402,405 | $415,808 | $708,531 |
| Stockholders' equity | $1.3M | $1.9M | $2.7M | $3.3M | $3.8M |
| Cash and investments | $1.6M | $2.6M | $1.8M | $2.3M | $2.9M |
| Total debt | — | — | $0 | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 28, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 8, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 27, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2026 | Aug 19, 2026 |
All 723 Hepion Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.